The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy
✍ Scribed by Gunar K. Zagars; Fady B. Geara; Alan Pollack; Andrew C. Von Eschenbach
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 765 KB
- Volume
- 73
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Background. This study was performed to evaluate the use of the 1992 International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) T categories for localized prostate cancer treated with radiation therapy and to compare the prognostic power of this system with the Whitmore-Jewett scheme.
Methods. The outcome for 427 men with Stages A2-C or Tla-T4b prostate cancers, followed for a mean of 32 months after treatment, was evaluated for relapse or rising prostate-specific antigen (PSA) levels, disease relapse, metastatic failure, and local recurrence relative to the two staging systems. Univariate and multivariate analysis was used to compare the two staging systems. The T categories were based on digital rectal examination.
Results. At 5 years, the actuarial incidence of relapse or rising PSA level was as follows: Stage A2, 29%; Stage B, 41%; Stage C, 62%. The corresponding results according to T category were as follows: Tla, 0%;